A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis

Kenneth B. Gordon*, Craig L. Leonardi, Mark Lebwohl, Andrew Blauvelt, Gregory S. Cameron, Daniel Braun, Janelle Erickson, Michael Heffernan

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

94 Scopus citations

Fingerprint

Dive into the research topics of 'A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis'. Together they form a unique fingerprint.

Nursing and Health Professions

Pharmacology, Toxicology and Pharmaceutical Science

INIS